TOLMAR Inc.

Belkins
TOLMAR is a Northern Colorado based pharmaceutical research, development, manufacturing and commercial operations company. TOLMAR develops and manufactures both proprietary and generic pharmaceutical products with specific focus in dermatology, oncology, and specialty injectable therapeutic areas.

Related News

INTEC PHARMA ANNOUNCES NEW RESEARCH COLLABORATION AGREEMENT WITH MSD

Intec Pharma | October 08, 2020

news image

Intec Pharma Ltd. ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential. "We are very excited to continue to work with MSD," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "This new agreement builds upon the relationship we have enjoyed in prior research and allows t...

Read More

UPCOMING XTALKS WEBINAR WILL DISCUSS PHARMACEUTICAL COMMERCIAL LAUNCH READINESS WITH SECRETS TO DE-RISK AND ACCELERATE SUCCESS

XTALKS | July 18, 2020

news image

Commercial launch readiness is a critical stage in a product life cycle. While the world hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will only increase price pressures overall for the industry. The era of increasing competitive and price pressure is not going away and capturing full value from every product launch is critical. However, history shows that only a third of product launches meet analyst expectations. Teams with the ability to opt...

Read More

PHARMA TITANS TEAM TO TACKLE COVID-19

Precision Vaccinations | April 14, 2020

news image

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mech...

Read More

AZ RECRUITS IMAGINAB IN CD8 IMMUNOPET DEAL

PharmaTimes | March 30, 2020

news image

AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology. The companies say that under the terms of the agreement, the technology will be used in AstraZeneca’s clinical trials in Europe and North America to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET. CD8 ImmunoPET ...

Read More

Intec Pharma | October 08, 2020

news image

INTEC PHARMA ANNOUNCES NEW RESEARCH COLLABORATION AGREEMENT WITH MSD

Intec Pharma Ltd. ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential. "We are very excited to continue to work with MSD," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "This new agreement builds upon the relationship we have enjoyed in prior research and allows t...

Read More

XTALKS | July 18, 2020

news image

UPCOMING XTALKS WEBINAR WILL DISCUSS PHARMACEUTICAL COMMERCIAL LAUNCH READINESS WITH SECRETS TO DE-RISK AND ACCELERATE SUCCESS

Commercial launch readiness is a critical stage in a product life cycle. While the world hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will only increase price pressures overall for the industry. The era of increasing competitive and price pressure is not going away and capturing full value from every product launch is critical. However, history shows that only a third of product launches meet analyst expectations. Teams with the ability to opt...

Read More

Precision Vaccinations | April 14, 2020

news image

PHARMA TITANS TEAM TO TACKLE COVID-19

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mech...

Read More

PharmaTimes | March 30, 2020

news image

AZ RECRUITS IMAGINAB IN CD8 IMMUNOPET DEAL

AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology. The companies say that under the terms of the agreement, the technology will be used in AstraZeneca’s clinical trials in Europe and North America to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET. CD8 ImmunoPET ...

Read More